Report cover image

Cell Therapy Human Raw Materials Market

Publisher Grand View Research
Published Feb 26, 2026
Length 120 Pages
SKU # GV21005736

Description

Size, Share & Trends Analysis Report By Product (Cell Culture Media, Cell Culture Sera, Cell Culture Supplements, Reagents & Buffers), By End Use (CROs & CMOs, Academic & Research Institutions), By Region, And Segment Forecasts, 2026 - 2033

Cell Therapy Human Raw Materials Market Summary

The global cell therapy human raw materials market was size valued at USD 4.37 billion in 2025 and is projected to reach USD 16.79 billion by 2033, expanding at a CAGR of 18.44% from 2026 to 2033. The increasing prevalence of chronic diseases such as cancer, diabetes, & autoimmune disorders, the growing demand for regenerative and personalized medicines, rising R&D activities, and increasing investments are anticipated to boost the cell therapy human raw materials market over the forecast period.

Global Cell Therapy Human Raw Materials Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the cell therapy human raw materials market on the basis of products, end use, and region.
  • Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Cell Culture Media
  • Cell Culture Sera
  • Cell Culture Supplements
  • Proteins
  • Growth Factors
  • Nucleotides
  • Other Supplements
  • Reagents & Buffers
  • Other Raw Materials
  • End Use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Biopharmaceutical & Pharmaceutical Companies
  • CROs & CMOs
  • Academic & Research Institutions
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
  • Latin America
  • Brazil
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

120 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Product
1.1.2. End Use
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objective
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis:
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. MARKET DRIVER ANALYSIS
3.2.1.1. Rapid growth of the cell therapy pipeline
3.2.1.2. Expansion of regenerative medicine and personalized medicine
3.2.1.3. Growing prevalence of immune-related disorders
3.2.2. MARKET RESTRAINT ANALYSIS
3.2.2.1. Ethical concerns related to stem cell research
3.2.2.2. High cost associated with the production and procurement of raw materials
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
Chapter 4. Product Business Analysis
4.1. Cell Therapy Human Raw Materials Market: Product Movement Analysis
4.2. Cell Culture Media
4.2.1. Cell culture media market estimates and forecasts, 2021 - 2033 (USD Million)
4.3. Cell Culture Sera
4.3.1. Cell culture sera market estimates and forecasts, 2021 - 2033 (USD Million)
4.4. Cell Culture Supplements
4.4.1. Cell culture supplements market estimates and forecasts, 2021 - 2033 (USD Million)
4.4.2. Proteins
4.4.2.1. Proteins market estimates and forecasts, 2021 - 2033 (USD Million)
4.4.3. Growth Factors
4.4.3.1. Growth factors market estimates and forecasts, 2021 - 2033 (USD Million)
4.4.4. Nucleotides
4.4.4.1. Nucleotides market estimates and forecasts, 2021 - 2033 (USD Million)
4.4.5. Other Supplements
4.4.5.1. Other supplements market estimates and forecasts, 2021 - 2033 (USD Million)
4.5. Reagents & Buffers
4.5.1. Reagents & buffers market estimates and forecasts, 2021 - 2033 (USD Million)
4.6. Other Raw Materials
4.6.1. Other raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 5. End Use Group Business Analysis
5.1. Cell Therapy Human Raw Materials Market: End Use Movement Analysis
5.2. Biopharmaceutical & Pharmaceutical Companies
5.2.1. Biopharmaceutical & pharmaceutical companies market estimates and forecasts, 2021 - 2033 (USD Million)
5.3. CROs & CMOs
5.3.1. CROS & CMOs market estimates and forecasts, 2021 - 2033 (USD Million)
5.4. Academic & Research Institutions
5.4.1. Academic & research institutions market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 6. Regional Business Analysis
6.1. Cell Therapy Human Raw Materials Share By Region, 2025 & 2033
6.2. North America
6.2.1. North America Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.2.2. U.S.
6.2.2.1. Key Country Dynamics
6.2.2.2. Competitive Scenario
6.2.2.3. Regulatory Framework
6.2.2.4. Target Disease Prevalence
6.2.2.5. U.S. Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.2.3. Canada
6.2.3.1. Key Country Dynamics
6.2.3.2. Competitive Scenario
6.2.3.3. Regulatory Framework
6.2.3.4. Target Disease Prevalence
6.2.3.5. Canada Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.2.4. Mexico
6.2.4.1. Key Country Dynamics
6.2.4.2. Competitive Scenario
6.2.4.3. Regulatory Framework
6.2.4.4. Target Disease Prevalence
6.2.4.5. Mexico Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.3. Europe
6.3.1. Europe Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.3.2. UK
6.3.2.1. Key Country Dynamics
6.3.2.2. Competitive Scenario
6.3.2.3. Regulatory Framework
6.3.2.4. Target Disease Prevalence
6.3.2.5. UK Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Competitive Scenario
6.3.3.3. Regulatory Framework
6.3.3.4. Target Disease Prevalence
6.3.3.5. Germany Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.3.4. France
6.3.4.1. Key Country Dynamics
6.3.4.2. Competitive Scenario
6.3.4.3. Regulatory Framework
6.3.4.4. Target Disease Prevalence
6.3.4.5. France Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.3.5. Italy
6.3.5.1. Key Country Dynamics
6.3.5.2. Competitive Scenario
6.3.5.3. Regulatory Framework
6.3.5.4. Target Disease Prevalence
6.3.5.5. Italy Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.3.6. Spain
6.3.6.1. Key Country Dynamics
6.3.6.2. Competitive Scenario
6.3.6.3. Regulatory Framework
6.3.6.4. Target Disease Prevalence
6.3.6.5. Spain Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.3.7. Denmark
6.3.7.1. Key Country Dynamics
6.3.7.2. Competitive Scenario
6.3.7.3. Regulatory Framework
6.3.7.4. Target Disease Prevalence
6.3.7.5. Denmark Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.3.8. Sweden
6.3.8.1. Key Country Dynamics
6.3.8.2. Competitive Scenario
6.3.8.3. Regulatory Framework
6.3.8.4. Target Disease Prevalence
6.3.8.5. Sweden Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.3.9. Norway
6.3.9.1. Key Country Dynamics
6.3.9.2. Competitive Scenario
6.3.9.3. Regulatory Framework
6.3.9.4. Target Disease Prevalence
6.3.9.5. Norway Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.4. Asia Pacific
6.4.1. Asia Pacific Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.4.2. Japan
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework
6.4.2.4. Target Disease Prevalence
6.4.2.5. Japan Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.4.3. China
6.4.3.1. Key Country Dynamics
6.4.3.2. Competitive Scenario
6.4.3.3. Regulatory Framework
6.4.3.4. Target Disease Prevalence
6.4.3.5. China Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.4.4. India
6.4.4.1. Key Country Dynamics
6.4.4.2. Competitive Scenario
6.4.4.3. Regulatory Framework
6.4.4.4. Target Disease Prevalence
6.4.4.5. India Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.4.5. Australia
6.4.5.1. Key Country Dynamics
6.4.5.2. Competitive Scenario
6.4.5.3. Regulatory Framework
6.4.5.4. Target Disease Prevalence
6.4.5.5. Australia Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.4.6. Thailand
6.4.6.1. Key Country Dynamics
6.4.6.2. Competitive Scenario
6.4.6.3. Regulatory Framework
6.4.6.4. Target Disease Prevalence
6.4.6.5. Thailand Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.4.7. South Korea
6.4.7.1. Key Country Dynamics
6.4.7.2. Competitive Scenario
6.4.7.3. Regulatory Framework
6.4.7.4. Target Disease Prevalence
6.4.7.5. South Korea Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.5. Latin America
6.5.1. Latin America Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.5.2. Brazil
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework
6.5.2.4. Target Disease Prevalence
6.5.2.5. Brazil Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.5.3. Argentina
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework
6.5.3.4. Target Disease Prevalence
6.5.3.5. Argentina Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.6. MEA
6.6.1. MEA Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.6.2. South Africa
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework
6.6.2.4. Target Disease Prevalence
6.6.2.5. South Africa Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.6.3. Saudi Arabia
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework
6.6.3.4. Target Disease Prevalence
6.6.3.5. Saudi Arabia Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.6.4. UAE
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework
6.6.4.4. Target Disease Prevalence
6.6.4.5. UAE Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
6.6.5. Kuwait
6.6.5.1. Key Country Dynamics
6.6.5.2. Competitive Scenario
6.6.5.3. Regulatory Framework
6.6.5.4. Target Disease Prevalence
6.6.5.5. Kuwait Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Market Position/Share Analysis, 2025
7.4. Company Profiles/Listing
7.4.1. Thermo Fisher Scientific, Inc
7.4.1.1. Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Merck KGaA
7.4.2.1. Overview
7.4.2.2. Financial Performance
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Actylis
7.4.3.1. Overview
7.4.3.2. Product Benchmarking
7.4.3.3. Strategic Initiatives
7.4.4. ACROBiosystems
7.4.4.1. Overview
7.4.4.2. Product Benchmarking
7.4.4.3. Strategic Initiatives
7.4.5. STEMCELL Technologies
7.4.5.1. Overview
7.4.5.2. Product Benchmarking
7.4.5.3. Strategic Initiatives
7.4.6. Grifols, S.A.
7.4.6.1. Overview
7.4.6.2. Financial Performance
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Charles River Laboratories
7.4.7.1. Overview
7.4.7.2. Financial Performance
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. RoosterBio, Inc.
7.4.8.1. Overview
7.4.8.2. Product Benchmarking
7.4.8.3. Strategic Initiatives
7.4.9. PromoCell GmbH
7.4.9.1. Overview
7.4.9.2. Product Benchmarking
7.4.9.3. Strategic Initiatives
7.4.10. Danaher
7.4.10.1. Overview
7.4.10.2. Financial Performance
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
7.4.11. BioIVT
7.4.11.1. Overview
7.4.11.2. Product Benchmarking
7.4.11.3. Strategic Initiatives
7.4.12. GeminiBio
7.4.12.1. Overview
7.4.12.2. Product Benchmarking
7.4.12.3. Strategic Initiatives
7.4.13. Akron Biotech
7.4.13.1. Overview
7.4.13.2. Product Benchmarking
7.4.13.3. Strategic Initiatives
7.4.14. AllCells
7.4.14.1. Overview
7.4.14.2. Product Benchmarking
7.4.14.3. Strategic Initiatives
7.4.15. CGT Global
7.4.15.1. Overview
7.4.15.2. Product Benchmarking
7.4.15.3. Strategic Initiatives

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us